These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 26846335)

  • 21. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
    Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
    Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
    Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
    BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
    Epstein Shochet G; Brook E; Eyal O; Edelstein E; Shitrit D
    Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1025-L1034. PubMed ID: 30810067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis.
    Ebrahimpour A; Ahir M; Wang M; Jegga AG; Bonnen MD; Eissa NT; Montesi SB; Raghu G; Ghebre YT
    Sci Rep; 2022 Nov; 12(1):20668. PubMed ID: 36450789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
    Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
    Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
    Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
    J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.
    Khalil N; Manganas H; Ryerson CJ; Shapera S; Cantin AM; Hernandez P; Turcotte EE; Parker JM; Moran JE; Albert GR; Sawtell R; Hagerimana A; Laurin P; Gagnon L; Cesari F; Kolb M
    Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of pirfenidone in a sheep model of pulmonary fibrosis.
    Dewage SNV; Organ L; Koumoundouros E; Derseh HB; Perera KUE; Samuel CS; Stent AW; Snibson KJ
    Exp Lung Res; 2019; 45(9-10):310-322. PubMed ID: 31762329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
    Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
    Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety of new drug treatments for idiopathic pulmonary fibrosis.
    Fletcher S; Jones MG; Spinks K; Sgalla G; Marshall BG; Limbrey R; Richeldi L
    Expert Opin Drug Saf; 2016 Nov; 15(11):1483-1489. PubMed ID: 27532218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
    Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.
    Conte E; Gili E; Fagone E; Fruciano M; Iemmolo M; Vancheri C
    Eur J Pharm Sci; 2014 Jul; 58():13-9. PubMed ID: 24613900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pirfenidone and nintedanib exert additive antifibrotic effects by the SPP1-AKT pathway in macrophages and fibroblasts.
    Meng C; Fan G; Liu J; Tao N; Sun T
    Biochem Biophys Res Commun; 2024 Jul; 716():150020. PubMed ID: 38692011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.
    Moor CC; Mostard RLM; Grutters JC; Bresser P; Aerts JGJV; Dirksen CD; Kimman ML; Wijsenbeek MS
    Respir Res; 2020 Jul; 21(1):196. PubMed ID: 32703201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1.
    Jin J; Togo S; Kadoya K; Tulafu M; Namba Y; Iwai M; Watanabe J; Nagahama K; Okabe T; Hidayat M; Kodama Y; Kitamura H; Ogura T; Kitamura N; Ikeo K; Sasaki S; Tominaga S; Takahashi K
    Respir Res; 2019 Jun; 20(1):119. PubMed ID: 31185973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.
    Holtze CH; Freiheit EA; Limb SL; Stauffer JL; Raimundo K; Pan WT; Flaherty KR; Kim HJ
    Respir Res; 2020 Feb; 21(1):48. PubMed ID: 32041621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.